Use of vitamin D analogs in chronic renal failure

Advances in Renal Replacement Therapy

Volumn 9, Issue 3, 2002, Pages 175-183

  Kim, George ^a   Sprague, Stuart M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; ALFACALCIDOL; CALCITRIOL; CALCIUM; DOXERCALCIFEROL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; VITAMIN D; VITAMIN D DERIVATIVE;

CHRONIC KIDNEY FAILURE; DIALYSIS; DRUG STRUCTURE; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; REVIEW; SECONDARY HYPERPARATHYROIDISM; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 0036653888     PISSN: 10734449     EISSN: None     Source Type: Journal    
DOI: 10.1053/jarr.2002.34844     Document Type: Article

References (64)

1. Renal osteodystrophy
2. Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure
3. Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis
4. Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D: A role for increased sensitivity to calcium
5. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro
6. Phosphorus restriction prevents parathyroid gland growth: High phosphorus directly stimulates PTH secretion in vitro
7. 1,25-Dihroxycholecalciferol and parathyroid hormone in advanced chronic renal failure: Effects of simultaneous protein and phosphorus restriction
8. 3 and ionized calcium in renal failure
9. Effect of dietary phosphorus on circulating concentrations of 1,25-dihyroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insuffiency
10. On the mechanism of secondary hyperparathyroidism in moderate renal insuffiency
11. 3 suppresses parathyroid hormone secretion from bovine parathyroid cells in tissue culture
12. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo by the rat
13. The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients
14. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients
15. Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol
16. Effects of vitamin D metabolites and analogues on renal function
17. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure
18. 3 administration in moderate renal failure: A prospective double blind trial
19. 3 in early renal failure
20. The hyperparathyroidism of chronic renal failure: A disorder of growth
21. Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis
22. Regulation of parathyroid hormone synthesis in chronic renal failure in rats
23. Reduced binding of [3H]1,25-dihyroxy-vitamin D 3 in the parathyroid glands of patients with renal failure
24. 3 receptors in experimental uremia
25. 2D receptors are decreased in parathyroid glands from chronically uremic dogs
26. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism
27. A comparison of oral and intravenous alfacalcidol in the treatment of uremic hyperparathyroidism
28. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD
29. Oral pulse calcitriol versus intravenous calcitriol therapy in treatment of hyperparathyroidism in hemodialysis patients
30. "Pulse oral" versus intravenous calcitriol therapy in chronic hemodialysis patients: A prospective and randomized study
31. 3 in experimental renal hyperparathyroidism
32. Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: A randomized prospective trial
33. A randomized trial of pulse versus daily oral calcitriol in CAPD patients
34. Guidelines for dosing of intravenous calcitriol in dialysis patients with hyperparathyroidism
35. Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol
36. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol
37. Long-term high dose intravenous calcitriol therapy in end-stage renal disease patients with severe secondary hyperparathyroidism
38. Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol
39. The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients
40. The importance of dosing intravenous calcitriol in dialysis patients with severe hyperparathyroidism
41. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: A cross-sectional study
42. The spectrum of bone disease in end-stage renal failure-an evolving disorder
43. 3, and radiology in end-stage renal disease
44. 3 intake: Emergence of an idiopathic adynamic bone disease not related to aluminum
45. The role of bone biopsy in the diagnosis of renal osteodystrophy
46. Aplastic osteodystrophy without aluminum. The role of suppressed parathyroid function
47. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone
48. Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic hemodialysis patients: A national study
49. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis
50. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group
51. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management
52. The noncalcemic analogue of vitamin D, 22-oxacalitriol, suppresses parathyroid hormone synthesis and secretion
53. The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine
54. Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: Results of a preliminary study
55. 2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats
56. 2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism
57. 2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content
58. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia
59. 2 on calcium and phosphorus resorption in bone
60. Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro
61. 2, a vitamin D analog with reduced bone resorbing activity in vitro
62. 2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis
63. Suppression of parathyroid hormone secretion in hemodialysis patients: Comparison of paricalcitol with calcitriol
64. Paricalcitol dosing according to body weight or severity of hyperparathyroidism: A double-blind, multicenter, randomized study